Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision oncology therapies using its proprietary AP3 platform. The company’s lead programs are ACR-368 and ACR-2316, and it also develops drug-tailored OncoSignature tests intended to match patients to the right therapy. Acrivon has not yet generated product revenue and is still funding research, clinical development, manufacturing scale-up, and regulatory preparation. Its business model is centered on advancing drug candidates through trials, then seeking approvals and, if successful, commercializing directly or through partnerships.

7.69

7.69

— Acrivon Therapeutics, Inc.
%
Clinical-stage drug candidates0% Small-molecule oncology assets in human trials, including ACR-368 and ACR-2316.
Precision medicine diagnostics0% OncoSignature tests designed to identify patients most likely to respond to Acrivon’s therapies.
Discovery platform0% The AP3 platform used to optimize compounds in intact cells and support pipeline generation.
Preclinical pipeline0% Earlier-stage drug discovery and validation programs that may become future clinical assets.
Manufacturing and development operations0% cGMP process development, clinical supply manufacturing, and scale-up activities for candidates.

Acrivon does not currently sell approved medicines, so its near-term “customers” are primarily clinical trial sites,...

  • Clinical development partnersprimary

    CROs, trial sites, and manufacturing partners that execute studies and produce clinical supply for ACR-368, ACR-2316, and related programs.

  • Future oncology prescribersprimary

    Oncologists and cancer centers that would prescribe approved products if Acrivon reaches commercialization.

  • Payers and reimbursement bodiessecondary

    Insurers and health systems that would influence uptake by deciding coverage and reimbursement for approved therapies.

  • Collaboration and licensing partnerssecondary

    Biopharma partners that may provide upfront fees, milestones, or R&D funding in exchange for rights or access.

  • Diagnostic usersemerging

    Clinicians and treatment centers that would use the OncoSignature test to identify likely responders.

Acrivon is a U.S.-based company and its reporting emphasizes operations and funding needs in the United States, where...

  • •Headquartered in the United States
  • •Clinical and regulatory execution is primarily U.S.-centric today
  • •Future approvals may be pursued in the United States and other jurisdictions
  • •No product revenue geography is disclosed because the company has no sales
  • •Geopolitical events can disrupt trials, supply, and operations

Acrivon’s strategy is to advance ACR-368 and ACR-2316 through clinical development while continuing to build a broader...

01
Clinical advancement of lead assetsshort-term

Clinical proof-of-concept is the main value driver because the company has no approved products or revenue.

02
Platform-driven pipeline expansionmedium-term

AP3-based discovery can create follow-on assets and reduce dependence on a single program.

03
Commercial and manufacturing readinessmedium-term

If a candidate is approved, the company must be able to supply, market, and distribute product.

04
Capital and partnership flexibilityshort-term

The company expects to need additional funding and may use collaborations to extend runway and reduce dilution.

Acrivon is a pre-revenue biotech with no approved products, so its core risk is that clinical candidates may fail, be...

critical

Clinical development failure

The company’s value depends on ACR-368, ACR-2316, and future candidates proving safe and effective in trials.

Scope
Lead oncology programs
Materiality
high
high

Financing and dilution risk

Acrivon expects to burn cash for years and may need equity, debt, or collaboration funding before commercialization.

Scope
Corporate funding
Materiality
high
high

Manufacturing and supply risk

Clinical and future commercial supply depends on cGMP process development and third-party manufacturing capacity.

Scope
Clinical supply and scale-up
Materiality
high
high

Regulatory approval risk

Even successful trials do not guarantee approval, and post-marketing studies or jurisdiction-specific requirements may add cost and delay.

Scope
FDA and other regulators
Materiality
high
medium

Intellectual property risk

The company relies on patents, licenses, and know-how to protect its platform and candidates from competitors.

Scope
AP3 platform and pipeline
Materiality
medium
medium

Geopolitical and trial disruption risk

Management explicitly cites public-health emergencies and geopolitical events as potential causes of trial and operational disruption.

Scope
Global trial operations
Materiality
medium
Research and development expense timing
High quarter-to-quarter volatility in operating results
Stock-based compensation
Reported losses and operating expense mix
License and collaboration obligations
Future expense and cash outflow uncertainty
Cash runway and going-concern style analysis
Liquidity and financing analysis

Aclaris Therapeutics, Inc.

ACRS · Pharmaceutical Preparations

Aptevo Therapeutics Inc.

APVO · Pharmaceutical Preparations

Bicara Therapeutics Inc.

BCAX · Pharmaceutical Preparations

Theriva Biologics, Inc.

TOVX · Pharmaceutical Preparations

Genprex, Inc.

GNPX · Pharmaceutical Preparations

LadRx Corp

Biological Products, (No Diagnostic Substances)

: 11/08/2026